Cosette Pharmaceuticals Announces the Approval and Launch of Metronidazole Gel USP, 1%.
Cosette Pharmaceuticals, Inc ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for Metronidazole Gel USP, 1%.
Cosette Pharmaceuticals Announces the launch of Griseofulvin Oral Suspension, 125 mg/5 mL.
Cosette Pharmaceuticals, Inc began shipping Griseofulvin Oral Suspension, 125 mg/5 mL (0713-0850-04) into all channels in the United States.
Cosette Pharmaceuticals Appoints Kevin Hickey, Vice President, Brand Sales and Marketing to Accelerate Transformation
“We are very excited to have Kevin Hickey join our team. His tremendous experience in strategy and execution of branded products will be instrumental as we integrate our eight cardio branded products through our transformative acquisition from Daiichi Sankyo and get ready for the imminent launches of several new products and lifecycle management strategies.” said Apurva Saraf, President and CEO, Cosette Pharmaceuticals.
Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity
Cosette announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette has already commenced commercial shipments, triggering the 180 days exclusivity.
Ganesh Pillarisetti has joined Cosette Pharmaceuticals as Vice President, IT
Ganesh Pillarisetti has joined the executive team as Vice President, IT at Cosette Pharmaceuticals. Ganesh will report to our President and CEO, Apurva Saraf, and will be based out of our office at South Plainfield, New Jersey. In this critical role, Ganesh's expertise in leveraging IT to streamline processes to increase both efficacy and efficiencies in our core areas of manufacturing, supply chain, quality, finance etc. will help us strongly deliver on our growth strategy of inorganic and organic growth through relentless execution.
Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth
Bridgewater, NJ. July 6, 2022. Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer (CFO), bolstering its executive leadership team.
Cosette Pharmaceuticals Receives U.S. Patent (US 11,291,628) For Welchol® Chewable Bar, A Novel Oral Drug Delivery System to Deliver Colesevelam Hcl
BRIDGEWATER, NJ – JUNE 7, 2022: Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,291,628 for Welchol® Chewable Bar, the Company’s novel drug delivery system of Colesevelam that is easy to handle and ingest, which provides patent protection until 2037.
Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva® (Docosanol Cream 10%) Including the First Approval in the Pump Format
Bridgewater, NJ and Vadodara, India May 24, 2022/PRNewswire/Cosette Pharmaceuticals, Inc ("Cosette"), in collaboration with Aleor Dermaceuticals, a wholly owned subsidiary of Alembic Pharmaceuticals (“Alembic”; BSE: 533573), announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for an NBE version of Abreva® (Docosanol cream 10%) in a 2 gm tube and pump formats. Shipments of the product will begin imminently.
